PL2279412T3 - Nowe kompozycje i sposoby leczenia chorób o podłożu immunologicznym - Google Patents

Nowe kompozycje i sposoby leczenia chorób o podłożu immunologicznym

Info

Publication number
PL2279412T3
PL2279412T3 PL09730709T PL09730709T PL2279412T3 PL 2279412 T3 PL2279412 T3 PL 2279412T3 PL 09730709 T PL09730709 T PL 09730709T PL 09730709 T PL09730709 T PL 09730709T PL 2279412 T3 PL2279412 T3 PL 2279412T3
Authority
PL
Poland
Prior art keywords
treatment
methods
related diseases
novel compositions
immune related
Prior art date
Application number
PL09730709T
Other languages
English (en)
Inventor
Hilary Clark
Dan Eaton
Lino Gonzalez Jr.
Jane L. Grogan
Jason Hackney
Kristin D. Harden
Xin Yu
Original Assignee
Genentech, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech, Inc. filed Critical Genentech, Inc.
Publication of PL2279412T3 publication Critical patent/PL2279412T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
PL09730709T 2008-04-09 2009-04-08 Nowe kompozycje i sposoby leczenia chorób o podłożu immunologicznym PL2279412T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US12353008P 2008-04-09 2008-04-09
US19427108P 2008-09-26 2008-09-26
PCT/US2009/039868 WO2009126688A2 (en) 2008-04-09 2009-04-08 Novel compositions and methods for the treatment of immune related diseases
EP09730709.4A EP2279412B1 (en) 2008-04-09 2009-04-08 Novel compositions and methods for the treatment of immune related diseases

Publications (1)

Publication Number Publication Date
PL2279412T3 true PL2279412T3 (pl) 2017-12-29

Family

ID=40873503

Family Applications (2)

Application Number Title Priority Date Filing Date
PL17152167T PL3208612T3 (pl) 2008-04-09 2009-04-08 Kompozycje i sposoby leczenia chorób o podłożu immunologicznym
PL09730709T PL2279412T3 (pl) 2008-04-09 2009-04-08 Nowe kompozycje i sposoby leczenia chorób o podłożu immunologicznym

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL17152167T PL3208612T3 (pl) 2008-04-09 2009-04-08 Kompozycje i sposoby leczenia chorób o podłożu immunologicznym

Country Status (18)

Country Link
US (5) US20090258013A1 (pl)
EP (3) EP3605088A1 (pl)
JP (7) JP5770624B2 (pl)
KR (4) KR101855381B1 (pl)
CN (3) CN110082533B (pl)
AU (1) AU2009233708B2 (pl)
BR (1) BRPI0906550B8 (pl)
CA (3) CA3179151A1 (pl)
DK (1) DK2279412T3 (pl)
ES (2) ES2640533T3 (pl)
HK (1) HK1211081A1 (pl)
HU (1) HUE036780T2 (pl)
IL (5) IL208285A0 (pl)
MX (3) MX364200B (pl)
PL (2) PL3208612T3 (pl)
SG (2) SG10202112838YA (pl)
SI (1) SI2279412T1 (pl)
WO (1) WO2009126688A2 (pl)

Families Citing this family (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2357505T3 (es) 2002-09-11 2011-04-27 Genentech, Inc. Composición y procedimientos novedosos para el tratamiento de enfermedades inmunorelacionadas.
CA3179151A1 (en) 2008-04-09 2009-10-15 Genentech, Inc. Novel compositions and methods for the treatment of immune related diseases
HUE061002T2 (hu) 2011-09-23 2023-04-28 Mereo Biopharma 5 Inc VEGF/DLL4-kötõ ágensek és alkalmazásaik
CA2892831A1 (en) * 2012-12-04 2014-06-12 Oncomed Pharmaceuticals, Inc. Immunotherapy with binding agents
RU2019129525A (ru) 2013-07-16 2019-11-05 Дженентек, Инк. Способы лечения рака с использованием антагонистов, связывающих с осью pd-1, и ингибиторов tigit
WO2015006811A2 (en) * 2013-07-19 2015-01-22 The Walter And Eliza Hall Institute Of Medical Research Diagnostic methods
JP2016530267A (ja) * 2013-08-22 2016-09-29 ザ・カウンシル・オヴ・ザ・クイーンズランド・インスティテュート・オヴ・メディカル・リサーチ 癌及びウイルス感染症を治療するための免疫受容体調節
AU2014308552B2 (en) * 2013-08-22 2020-02-13 The Council Of The Queensland Institute Of Medical Research Immunoreceptor modulation for treating cancer and viral infections
EP3036258B1 (en) * 2013-08-22 2023-07-19 The Council of the Queensland Institute of Medical Research Immunoreceptor modulation for treating cancer and viral infections
CN103487572B (zh) * 2013-10-08 2017-03-29 北京大学人民医院 滤泡辅助性T淋巴细胞(Tfh)在自身免疫性疾病病情预警中的应用
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
EP3119913B1 (en) * 2014-03-21 2021-01-06 The Brigham and Women's Hospital, Inc. Methods and compositions for treatment of immune-related diseases or disorders and/or therapy monitoring
US9885021B2 (en) 2014-06-12 2018-02-06 Children's National Medical Center Generation of broadly-specific, virus-immune cells targeting multiple HIV antigens for preventive and therapeutic use
JP2017522311A (ja) * 2014-07-16 2017-08-10 ジェネンテック， インコーポレイテッド Ｔｉｇｉｔ阻害剤及び抗癌剤を使用する癌の治療方法
MY184288A (en) * 2014-08-19 2021-03-30 Merck Sharp & Dohme Llc Anti-tigit antibodies
AU2015343494A1 (en) * 2014-11-06 2017-04-27 Genentech, Inc. Combination therapy comprising OX40 binding agonists and TIGIT inhibitors
BR112017013385A2 (pt) * 2014-12-23 2018-02-06 Bristol-Myers Squibb Company anticorpos para tigit
MA41460A (fr) 2015-02-03 2017-12-12 Oncomed Pharm Inc Agents de liaison à la tnfrsf et leurs utilisations
SG11201706583PA (en) 2015-02-19 2017-09-28 Compugen Ltd Anti-pvrig antibodies and methods of use
EP3259597B1 (en) 2015-02-19 2022-04-06 Compugen Ltd. Pvrig polypeptides and methods of treatment
EP3875477A1 (en) 2015-04-17 2021-09-08 Alpine Immune Sciences, Inc. Immunomodulatory proteins with tunable affinities
US11022615B2 (en) * 2015-05-04 2021-06-01 University Of Florida Research Foundation, Inc. Regulatory T-cells, method for their isolation and uses
TWI715587B (zh) * 2015-05-28 2021-01-11 美商安可美德藥物股份有限公司 Ｔｉｇｉｔ結合劑和彼之用途
UY36687A (es) 2015-05-29 2016-11-30 Bristol Myers Squibb Company Una Corporación Del Estado De Delaware Anticuerpos contra ox40 y sus usos
JO3620B1 (ar) * 2015-08-05 2020-08-27 Amgen Res Munich Gmbh مثبطات نقطة فحص مناعية للاستخدام في علاج سرطانات محمولة عبر الدم
EP3334757A4 (en) * 2015-08-14 2019-04-03 Merck Sharp & Dohme Corp. ANTI-TIGIT ANTIBODIES
CN107949573B (zh) 2015-09-01 2022-05-03 艾吉纳斯公司 抗-pd-1抗体及其使用方法
JP6861418B2 (ja) * 2015-09-02 2021-04-28 イッサム リサーチ デベロップメント カンパニー オブ ザ ヘブリュー ユニバーシティー オブ エルサレム リミテッド ヒトｔ細胞免疫グロブリン及びｉｔｉｍドメイン（ｔｉｇｉｔ）に特異的な抗体
AU2016322934A1 (en) * 2015-09-14 2018-04-12 Compass Therapeutics Llc Compositions and methods for treating cancer via antagonism of the CD155/TIGIT pathway and TGF-beta
EP3353204B1 (en) 2015-09-23 2023-10-18 Mereo BioPharma 5, Inc. Bi-specific anti-vegf/dll4 antibody for use in treating platinum-resistant ovarian cancer
CR20180225A (es) * 2015-09-25 2018-07-09 Genentech Inc Anticuerpo anti-tigit y métodos de uso
KR20180051651A (ko) * 2015-10-01 2018-05-16 히트 바이오로직스, 인코퍼레이티드 비상동성 키메라 단백질로서의 i형 및 ii형 세포외 도메인을 인접시키기 위한 조성물 및 방법
EP3356413B1 (en) * 2015-10-01 2022-01-05 Potenza Therapeutics, Inc. Anti-tigit antigen-binding proteins and methods of use thereof
JO3555B1 (ar) 2015-10-29 2020-07-05 Merck Sharp & Dohme جسم مضاد يبطل فعالية فيروس الالتهاب الرئوي البشري
RU2756275C2 (ru) 2016-03-01 2021-09-29 Юссум Рисёрч Девелопмент Компани Оф Зэ Хибру Юниверсити Оф Иерусалим Лтд. Антитела, специфические к рецептору полиовируса (pvr) человека
BR112018067458A2 (pt) 2016-03-04 2019-01-02 Abmuno Therapeutics Llc anticorpos para tigit
EA039540B1 (ru) * 2016-03-25 2022-02-08 Онкомед Фармасьютикалс, Инк. Связывающие tigit агенты и варианты их применения
JP2019521643A (ja) 2016-04-15 2019-08-08 アルパイン イミューン サイエンシズ インコーポレイテッド Ｃｄ８０バリアント免疫調節タンパク質およびその使用
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
MX2018016364A (es) 2016-06-20 2019-11-28 Kymab Ltd Anticuerpos anti-pd-l1.
WO2018017864A2 (en) * 2016-07-20 2018-01-25 Oncomed Pharmaceuticals, Inc. Pvrig-binding agents and uses thereof
US11471488B2 (en) 2016-07-28 2022-10-18 Alpine Immune Sciences, Inc. CD155 variant immunomodulatory proteins and uses thereof
US11834490B2 (en) 2016-07-28 2023-12-05 Alpine Immune Sciences, Inc. CD112 variant immunomodulatory proteins and uses thereof
US11858996B2 (en) 2016-08-09 2024-01-02 Kymab Limited Anti-ICOS antibodies
PL3347379T3 (pl) 2016-08-17 2020-05-18 Compugen Ltd. Przeciwciała anty-tigit, przeciwciała anty-pvrig i ich połączenia
WO2018041120A1 (en) * 2016-08-31 2018-03-08 Beijing Biocytogen Co., Ltd Genetically modified non-human animal with human or chimeric tigit
CN107815467B (zh) * 2016-08-31 2021-03-16 百奥赛图(北京)医药科技股份有限公司 人源化基因改造动物模型的制备方法及应用
WO2018083248A1 (en) 2016-11-03 2018-05-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
EP3548071A4 (en) 2016-11-30 2020-07-15 OncoMed Pharmaceuticals, Inc. METHOD FOR TREATING CANCER WITH TIGIT-BINDING ACTIVE SUBSTANCES
US10232053B2 (en) 2016-12-30 2019-03-19 Trieza Therapeutics, Inc. Immunomodulatory oncolytic adenoviral vectors, and methods of production and use thereof for treatment of cancer
WO2018127916A1 (en) 2017-01-05 2018-07-12 Kahr Medical Ltd. A pd1-cd70 fusion protein and methods of use thereof
KR102581439B1 (ko) 2017-01-05 2023-09-21 카 메디컬 리미티드 Sirp알파-41bbl 융합 단백질 및 이의 이용 방법
US11299530B2 (en) 2017-01-05 2022-04-12 Kahr Medical Ltd. SIRP alpha-CD70 fusion protein and methods of use thereof
CN110536693B (zh) 2017-01-05 2023-12-22 卡尔医学有限公司 Pd1-41bbl融合蛋白及使用其的方法
JOP20190203A1 (ar) 2017-03-30 2019-09-03 Potenza Therapeutics Inc بروتينات رابطة لمولد ضد مضادة لـ tigit وطرق استخدامها
WO2018195552A1 (en) 2017-04-21 2018-10-25 Sillajen, Inc. Oncolytic vaccinia virus and checkpoint inhibitor combination therapy
WO2018200430A1 (en) 2017-04-26 2018-11-01 Bristol-Myers Squibb Company Methods of antibody production that minimize disulfide bond reduction
US11021537B2 (en) 2017-05-01 2021-06-01 Agenus Inc. Anti-TIGIT antibodies and methods of use thereof
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
EP3618871A4 (en) 2017-05-02 2021-01-06 Merck Sharp & Dohme Corp. ANTI-LAG3 ANTIBODIES ETCO-FORMULATIONS ANTI-LAG3 ANTIBODIES AND ANTI-PD-1 ANTIBODIES
US11122042B1 (en) 2017-05-12 2021-09-14 F5 Networks, Inc. Methods for dynamically managing user access control and devices thereof
SG10202111336RA (en) 2017-06-01 2021-11-29 Compugen Ltd Triple combination antibody therapies
GB201709808D0 (en) 2017-06-20 2017-08-02 Kymab Ltd Antibodies
MX2020000960A (es) 2017-07-27 2020-07-22 iTeos Belgium SA Anticuerpos anti-tigit.
CN111051347B (zh) 2017-09-29 2021-12-21 江苏恒瑞医药股份有限公司 Tigit抗体、其抗原结合片段及医药用途
US11753458B2 (en) 2017-10-10 2023-09-12 Alpine Immune Sciences, Inc. CTLA-4 variant immunomodulatory proteins and uses thereof
CN107988255A (zh) * 2017-10-20 2018-05-04 深圳市龙岗区妇幼保健院 一种确定atr与erk结合区域的方法
WO2019122882A1 (en) 2017-12-19 2019-06-27 Kymab Limited Bispecific antibody for icos and pd-l1
MX2020008795A (es) 2018-02-28 2020-10-08 Yuhan Corp Anti cuerpos anti tigit y usos de los mismos.
KR20200016114A (ko) 2018-08-06 2020-02-14 선일이씨티 주식회사 생물접촉 순환여과 방식의 오폐수 고도처리 시스템
SG11202101429YA (en) 2018-08-23 2021-03-30 Seagen Inc Anti-tigit antibodies
AR117327A1 (es) 2018-12-20 2021-07-28 23Andme Inc Anticuerpos anti-cd96 y métodos de uso de estos
CN110156888B (zh) * 2019-05-13 2021-07-30 沣潮医药科技（上海）有限公司 Cd96重组蛋白在制备针对免疫性疾病药物组合物中的用途
EP4001308A4 (en) 2019-07-15 2023-08-23 Shanghai Junshi Biosciences Co., Ltd. ANTI-TIGIT ANTIBODIES AND THEIR APPLICATION
CN112625130B (zh) 2019-09-24 2023-08-29 财团法人工业技术研究院 抗-tigit抗体及使用之方法
KR20220070011A (ko) 2019-09-27 2022-05-27 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 항원 결합 단백질
CN114746446A (zh) * 2019-11-21 2022-07-12 百济神州有限公司 使用抗ox40抗体与抗tigit抗体组合治疗癌症的方法
CA3170025A1 (en) 2020-03-13 2021-09-16 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Pvrig binding protein and its medical uses
CN113563470B (zh) 2020-04-29 2023-02-10 广州昂科免疫生物技术有限公司 结合tigit抗原的抗体及其制备方法与应用
EP4157875A1 (en) 2020-06-02 2023-04-05 Arcus Biosciences, Inc. Antibodies to tigit
US20210395366A1 (en) 2020-06-18 2021-12-23 Genentech, Inc. Treatment with anti-tigit antibodies and pd-1 axis binding antagonists
TW202216778A (zh) 2020-07-15 2022-05-01 美商安進公司 Ｔｉｇｉｔ及ｃｄ１１２ｒ阻斷
CN111763660A (zh) * 2020-08-07 2020-10-13 南京大学 一种重组溶瘤痘苗病毒及其制备方法和应用
WO2022044010A1 (en) 2020-08-26 2022-03-03 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Anti-t-cell immunoglobulin and itim domain (tigit) antibodies for the treatment of fungal infections
CN116406292A (zh) * 2020-10-09 2023-07-07 学校法人庆应义塾 免疫·炎症性疾病的治疗药
CN112294946B (zh) * 2020-10-28 2023-02-10 中国人民解放军空军军医大学 可溶性重组蛋白cd226-ecd抑制过敏性鼻炎哮喘综合征的制药应用
TW202233248A (zh) 2020-11-08 2022-09-01 美商西健公司 組合療法
US20240067720A1 (en) 2021-01-14 2024-02-29 Shanghai Junshi Biosciences Co., Ltd. Anti-tigit antibody pharmaceutical composition and application thereof
CN117136258A (zh) 2021-03-31 2023-11-28 泷搌（上海）生物科技有限公司 用于筛选功能性抗原结合蛋白的载体和方法
CN117730097A (zh) 2021-04-09 2024-03-19 思进公司 以抗tigit抗体治疗癌症的方法
TW202304965A (zh) 2021-05-04 2023-02-01 美商艾吉納斯公司 抗ｔｉｇｉｔ抗體、抗ｃｄ９６抗體及其使用方法
TW202309078A (zh) 2021-07-02 2023-03-01 美商建南德克公司 治療癌症之方法及組成物
WO2023010094A2 (en) 2021-07-28 2023-02-02 Genentech, Inc. Methods and compositions for treating cancer
CA3224180A1 (en) 2021-07-28 2023-02-02 F. Hoffmann-La Roche Ag Methods and compositions for treating cancer
WO2023014360A1 (en) * 2021-08-05 2023-02-09 Octagon Therapeutics, Inc. Treatment and diagnosis of immune disorders relating to aberrant immune cells
WO2023040935A1 (zh) 2021-09-15 2023-03-23 江苏恒瑞医药股份有限公司 一种含抗pvrig/tigit双特异性抗体的药物组合物
TW202328195A (zh) 2021-09-15 2023-07-16 大陸商江蘇恆瑞醫藥股份有限公司 特異性結合ｐｄ－１的蛋白及其醫藥用途
TW202321308A (zh) 2021-09-30 2023-06-01 美商建南德克公司 使用抗ｔｉｇｉｔ抗體、抗ｃｄ３８抗體及ｐｄ—１軸結合拮抗劑治療血液癌症的方法
WO2023170606A1 (en) 2022-03-08 2023-09-14 Alentis Therapeutics Ag Use of anti-claudin-1 antibodies to increase t cell availability
WO2023178192A1 (en) 2022-03-15 2023-09-21 Compugen Ltd. Il-18bp antagonist antibodies and their use in monotherapy and combination therapy in the treatment of cancer
WO2023240058A2 (en) 2022-06-07 2023-12-14 Genentech, Inc. Prognostic and therapeutic methods for cancer

Family Cites Families (171)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1516629A (en) * 1924-11-25 Ernest blaker
US2408528A (en) * 1945-01-16 1946-10-01 Nassour Edward Race recording system
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US3896111A (en) 1973-02-20 1975-07-22 Research Corp Ansa macrolides
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4151042A (en) 1977-03-31 1979-04-24 Takeda Chemical Industries, Ltd. Method for producing maytansinol and its derivatives
US4137230A (en) 1977-11-14 1979-01-30 Takeda Chemical Industries, Ltd. Method for the production of maytansinoids
FR2413974A1 (fr) 1978-01-06 1979-08-03 David Bernard Sechoir pour feuilles imprimees par serigraphie
US4265814A (en) 1978-03-24 1981-05-05 Takeda Chemical Industries Matansinol 3-n-hexadecanoate
US4307016A (en) 1978-03-24 1981-12-22 Takeda Chemical Industries, Ltd. Demethyl maytansinoids
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
JPS5562090A (en) 1978-10-27 1980-05-10 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
US4256746A (en) 1978-11-14 1981-03-17 Takeda Chemical Industries Dechloromaytansinoids, their pharmaceutical compositions and method of use
JPS5566585A (en) 1978-11-14 1980-05-20 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS55164687A (en) 1979-06-11 1980-12-22 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS55102583A (en) 1979-01-31 1980-08-05 Takeda Chem Ind Ltd 20-acyloxy-20-demethylmaytansinoid compound
JPS55162791A (en) 1979-06-05 1980-12-18 Takeda Chem Ind Ltd Antibiotic c-15003pnd and its preparation
JPS55164685A (en) 1979-06-08 1980-12-22 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS55164686A (en) 1979-06-11 1980-12-22 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4309428A (en) 1979-07-30 1982-01-05 Takeda Chemical Industries, Ltd. Maytansinoids
JPS5645483A (en) 1979-09-19 1981-04-25 Takeda Chem Ind Ltd C-15003phm and its preparation
EP0028683A1 (en) 1979-09-21 1981-05-20 Takeda Chemical Industries, Ltd. Antibiotic C-15003 PHO and production thereof
JPS5645485A (en) 1979-09-21 1981-04-25 Takeda Chem Ind Ltd Production of c-15003pnd
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
ZA811368B (en) 1980-03-24 1982-04-28 Genentech Inc Bacterial polypedtide expression employing tryptophan promoter-operator
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
WO1982001188A1 (en) 1980-10-08 1982-04-15 Takeda Chemical Industries Ltd 4,5-deoxymaytansinoide compounds and process for preparing same
US4450254A (en) 1980-11-03 1984-05-22 Standard Oil Company Impact improvement of high nitrile resins
US4315929A (en) 1981-01-27 1982-02-16 The United States Of America As Represented By The Secretary Of Agriculture Method of controlling the European corn borer with trewiasine
US4313946A (en) 1981-01-27 1982-02-02 The United States Of America As Represented By The Secretary Of Agriculture Chemotherapeutically active maytansinoids from Trewia nudiflora
JPS57192389A (en) 1981-05-20 1982-11-26 Takeda Chem Ind Ltd Novel maytansinoid
US4873191A (en) 1981-06-12 1989-10-10 Ohio University Genetic transformation of zygotes
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
NZ201705A (en) 1981-08-31 1986-03-14 Genentech Inc Recombinant dna method for production of hepatitis b surface antigen in yeast
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4943529A (en) 1982-05-19 1990-07-24 Gist-Brocades Nv Kluyveromyces as a host strain
AU2353384A (en) 1983-01-19 1984-07-26 Genentech Inc. Amplification in eukaryotic host cells
US4713339A (en) 1983-01-19 1987-12-15 Genentech, Inc. Polycistronic expression vector construction
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4675187A (en) 1983-05-16 1987-06-23 Bristol-Myers Company BBM-1675, a new antibiotic complex
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
AU3145184A (en) 1983-08-16 1985-02-21 Zymogenetics Inc. High expression of foreign genes in schizosaccharomyces pombe
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4736866A (en) 1984-06-22 1988-04-12 President And Fellows Of Harvard College Transgenic non-human mammals
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
US4970198A (en) 1985-10-17 1990-11-13 American Cyanamid Company Antitumor antibiotics (LL-E33288 complex)
DE3675588D1 (de) 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
JPS63502716A (ja) 1986-03-07 1988-10-13 マサチューセッツ・インステチュート・オブ・テクノロジー 糖タンパク安定性の強化方法
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US4946783A (en) 1987-01-30 1990-08-07 President And Fellows Of Harvard College Periplasmic protease mutants of Escherichia coli
US5079233A (en) 1987-01-30 1992-01-07 American Cyanamid Company N-acyl derivatives of the LL-E33288 antitumor antibiotics, composition and methods for using the same
US5010182A (en) 1987-07-28 1991-04-23 Chiron Corporation DNA constructs containing a Kluyveromyces alpha factor leader sequence for directing secretion of heterologous polypeptides
US4975278A (en) 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
GB8724885D0 (en) 1987-10-23 1987-11-25 Binns M M Fowlpox virus promotors
US5770701A (en) 1987-10-30 1998-06-23 American Cyanamid Company Process for preparing targeted forms of methyltrithio antitumor agents
US5053394A (en) 1988-09-21 1991-10-01 American Cyanamid Company Targeted forms of methyltrithio antitumor agents
US5606040A (en) 1987-10-30 1997-02-25 American Cyanamid Company Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
WO1989005859A1 (en) 1987-12-21 1989-06-29 The Upjohn Company Agrobacterium mediated transformation of germinating plant seeds
AU4005289A (en) 1988-08-25 1990-03-01 Smithkline Beecham Corporation Recombinant saccharomyces
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
ATE144281T1 (de) 1989-04-28 1996-11-15 Rhein Biotech Proz & Prod Gmbh Hefezellen der gattung-schwanniomyces
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
ES2096590T3 (es) 1989-06-29 1997-03-16 Medarex Inc Reactivos biespecificos para la terapia del sida.
FR2649120B1 (fr) 1989-06-30 1994-01-28 Cayla Nouvelle souche et ses mutants de champignons filamenteux, procede de production de proteines recombinantes a l'aide de ladite souche et souches et proteines obtenues selon ce procede
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
CA2026147C (en) 1989-10-25 2006-02-07 Ravi J. Chari Cytotoxic agents comprising maytansinoids and their therapeutic use
DE69128350T2 (de) 1990-06-11 1998-03-26 Nexstar Pharmaceuticals Inc Nukleinsäureliganden
EP0546073B1 (en) 1990-08-29 1997-09-10 GenPharm International, Inc. production and use of transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5206161A (en) 1991-02-01 1993-04-27 Genentech, Inc. Human plasma carboxypeptidase B
EP0586505A1 (en) 1991-05-14 1994-03-16 Repligen Corporation Heteroconjugate antibodies for treatment of hiv infection
US5362852A (en) 1991-09-27 1994-11-08 Pfizer Inc. Modified peptide derivatives conjugated at 2-hydroxyethylamine moieties
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
DE69233528T2 (de) 1991-11-25 2006-03-16 Enzon, Inc. Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen
ZA932522B (en) 1992-04-10 1993-12-20 Res Dev Foundation Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
JP3095175B2 (ja) 1992-11-13 2000-10-03 アイデック ファーマシューティカルズ コーポレイション Ｂ細胞リンパ腫の治療のためのヒトｂリンパ球限定分化抗原に対するキメラ抗体と放射能標識抗体の療法利用
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
EP0616812B1 (en) 1993-03-24 1999-11-03 Berlex Biosciences Combination with anti-hormonal compounds and binding molecules for the treatment of cancer
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
US5989811A (en) 1994-09-29 1999-11-23 Urocor, Inc. Sextant core biopsy predictive mechanism for non-organ confined disease status
US5663149A (en) 1994-12-13 1997-09-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US5712374A (en) 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
US5750345A (en) 1995-10-31 1998-05-12 Evanston Hospital Corporation Detection of human α-thalassemia mutations and their use as predictors of blood-related disorders
WO1997033551A2 (en) 1996-03-15 1997-09-18 Millennium Pharmaceuticals Compositions and methods for the diagnosis, prevention, and treatment of neoplastic cell growth and proliferation
DK1516629T3 (da) * 1996-11-27 2013-06-03 Genentech Inc Humaniseret anti-CD-11a antibodies
WO1999063063A1 (en) * 1998-06-03 1999-12-09 Northwestern University Cellular proteins which mediate herpesvirus entry
US6518033B1 (en) 1998-08-05 2003-02-11 The Research Foundation Of State University Of New York Method of detecting the presence of CD155 for diagnosis of cancer and to determine treatment
JP2004516227A (ja) 1999-03-08 2004-06-03 ジェネンテック・インコーポレーテッド 免疫関連疾患を治療するための組成物と方法
CA2368467A1 (en) 1999-03-26 2000-10-05 Human Genome Sciences, Inc. 50 human secreted proteins
US7282570B2 (en) 1999-04-20 2007-10-16 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
ES2291198T3 (es) * 1999-07-20 2008-03-01 Genentech, Inc. Composiciones y procedimientos para el tratamiento de enfermedades de tipo inmunologico.
US20080050809A1 (en) * 1999-09-28 2008-02-28 Alejandro Abuin Novel human kinases and polynucleotides encoding the same
AU1220001A (en) 1999-10-20 2001-04-30 Zymogenetics Inc. Novel proteins and polynucleotides encoding them
US20040219521A1 (en) * 2000-01-21 2004-11-04 Tang Y. Tom Novel nucleic acids and polypeptides
IL151865A0 (en) 2000-03-31 2003-04-10 Genentech Inc Compositions and methods for detecting and quantifying gene expression
AU2001249673A1 (en) 2000-04-04 2001-10-15 Schering Corporation Isolated nucleic acids from micromonospora rosaria plasmid pmr2 and vectors made therefrom
MXPA02012106A (es) 2000-06-06 2003-06-06 Bristol Myers Squibb Co Polipeptidos y acidos nucleicos relacionados con b7 empleados para inmunomodulacion.
US7713705B2 (en) 2002-12-24 2010-05-11 Biosite, Inc. Markers for differential diagnosis and methods of use thereof
US6884869B2 (en) 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
WO2002099062A2 (en) * 2001-06-04 2002-12-12 Curagen Corporation Novel antibodies that bind to antigenic polypeptides, nucleic acids encoding the antigens, and methods of use
US20040101876A1 (en) * 2002-05-31 2004-05-27 Liat Mintz Methods and systems for annotating biomolecular sequences
AU2002366951A1 (en) 2001-12-10 2003-07-09 Nuvelo,Inc. Novel nucleic acids and polypeptides
AU2003211112A1 (en) 2002-02-13 2003-09-04 Incyte Corporation Secreted proteins
JP2005535290A (ja) * 2002-02-22 2005-11-24 ジェネンテック・インコーポレーテッド 免疫関連疾患の治療のための組成物と方法
US7193069B2 (en) * 2002-03-22 2007-03-20 Research Association For Biotechnology Full-length cDNA
PT1537878E (pt) 2002-07-03 2010-11-18 Ono Pharmaceutical Co Composições de imunopotenciação
JP4395570B2 (ja) * 2002-07-30 2010-01-13 独立行政法人産業技術総合研究所 水の熱化学的分解による水素の製造方法
EP1391213A1 (en) 2002-08-21 2004-02-25 Boehringer Ingelheim International GmbH Compositions and methods for treating cancer using maytansinoid CD44 antibody immunoconjugates and chemotherapeutic agents
ES2357505T3 (es) 2002-09-11 2011-04-27 Genentech, Inc. Composición y procedimientos novedosos para el tratamiento de enfermedades inmunorelacionadas.
CA2497334A1 (en) * 2002-09-11 2004-03-25 Genentech, Inc. Novel compositions and methods for the treatment of immune related diseases
CN1720336A (zh) * 2002-10-03 2006-01-11 健泰科生物技术公司 A33抗原以及jam－it的用途
US6925898B2 (en) * 2002-10-18 2005-08-09 Logitech Europe S.A. Variable sensor shaft retention apparatus
EP1481993A1 (en) 2003-05-28 2004-12-01 Xerion Pharmaceuticals AG Modulation of the poliovirus receptor function
US7144032B2 (en) * 2003-09-09 2006-12-05 Autoliv Asp, Inc. Expandable pelvic side airbag
AR046639A1 (es) * 2003-11-21 2005-12-14 Schering Corp Combinaciones terapeuticas de anticuerpo anti- igfr1
EP1687336A2 (en) * 2003-11-28 2006-08-09 AstraZeneca AB Antibodies
CN101035807A (zh) * 2004-06-09 2007-09-12 泰勒公司 Siglec－6相关疾病的诊断和治疗
US7096772B2 (en) * 2004-08-30 2006-08-29 Caterpillar S.A.R.L. System and method for controlling hydraulic fluid flow
GT200500283A (es) * 2004-10-08 2006-05-08 Inmunoterapia de desordenes autoinmunes
KR101498834B1 (ko) 2005-05-09 2015-03-05 오노 야꾸힝 고교 가부시키가이샤 예정 사멸 인자 1(ｐｄ-1)에 대한 인간 모노클로날 항체, 및 항-ｐｄ-1 항체를 단독 사용하거나 기타 면역 요법제와 병용한 암 치료 방법
US20070054360A1 (en) 2005-05-12 2007-03-08 Zeren Gao Compositions and methods for modulating immune responses
HUE026039T2 (en) 2005-07-01 2016-05-30 Squibb & Sons Llc Human monoclonal antibodies programmed for death ligand 1 (PD-L1)
JP2009538120A (ja) 2006-04-13 2009-11-05 ザイモジェネティクス， インコーポレイテッド 四量体化ポリペプチドおよび使用方法
US20100075377A1 (en) 2006-04-13 2010-03-25 West James W Tetramerizing polypeptides and methods of use
US20070243584A1 (en) 2006-04-13 2007-10-18 West James W Tetramerizing polypeptides and methods of use
WO2007124383A2 (en) 2006-04-19 2007-11-01 Oregon Health & Science University 1,1'-binaphthyl-based inhibitors of nad+-dependent deacetylase activity and sir2-family members
CA3179151A1 (en) 2008-04-09 2009-10-15 Genentech, Inc. Novel compositions and methods for the treatment of immune related diseases
TWI686405B (zh) 2008-12-09 2020-03-01 建南德克公司 抗ｐｄ-ｌ１抗體及其於增進ｔ細胞功能之用途
US20130017199A1 (en) 2009-11-24 2013-01-17 AMPLIMMUNE ,Inc. a corporation Simultaneous inhibition of pd-l1/pd-l2
CN103168048B (zh) 2010-06-09 2017-02-15 酶原遗传学有限公司 二聚vstm3融合蛋白和相关的组合物和方法
EA026924B1 (ru) 2011-08-01 2017-05-31 Дженентек, Инк. Способы лечения рака с использованием антагонистов, связывающихся с осью pd-1, и ингибиторов mek
EP2812022B1 (en) 2012-02-06 2019-06-26 Providence Health & Services - Oregon Method of monitoring cancer treatment using ox40 agonists
PT2925350T (pt) 2012-12-03 2019-03-25 Bristol Myers Squibb Co Melhoria da atividade anticancerosa de proteínas de fusão de fc imunomoduladoras
CA2892831A1 (en) 2012-12-04 2014-06-12 Oncomed Pharmaceuticals, Inc. Immunotherapy with binding agents
CN103073644B (zh) 2012-12-31 2014-03-12 中国科学技术大学 特异性抗小鼠tigit的单克隆抗体及其制备方法、鉴定及应用
WO2014116846A2 (en) 2013-01-23 2014-07-31 Abbvie, Inc. Methods and compositions for modulating an immune response
WO2014151006A2 (en) 2013-03-15 2014-09-25 Genentech, Inc. Biomarkers and methods of treating pd-1 and pd-l1 related conditions
RU2019129525A (ru) 2013-07-16 2019-11-05 Дженентек, Инк. Способы лечения рака с использованием антагонистов, связывающих с осью pd-1, и ингибиторов tigit
EP3043819A4 (en) 2013-09-11 2017-04-05 Compugen Ltd. Anti-vstm5 antibodies and the use thereof in therapy and diagnosis
CN106132439A (zh) 2014-03-31 2016-11-16 豪夫迈·罗氏有限公司 包含抗血管发生剂和ox40结合激动剂的组合疗法
MA40682B1 (fr) 2014-03-31 2020-01-31 Hoffmann La Roche Anticorps anti-ox40 et procédés d'utilisation correspondants
JP2017522311A (ja) 2014-07-16 2017-08-10 ジェネンテック， インコーポレイテッド Ｔｉｇｉｔ阻害剤及び抗癌剤を使用する癌の治療方法
MY184288A (en) 2014-08-19 2021-03-30 Merck Sharp & Dohme Llc Anti-tigit antibodies
BR112017006664A2 (pt) 2014-10-03 2017-12-26 Novartis Ag terapias de combinação
AU2015343494A1 (en) 2014-11-06 2017-04-27 Genentech, Inc. Combination therapy comprising OX40 binding agonists and TIGIT inhibitors
BR112017013385A2 (pt) 2014-12-23 2018-02-06 Bristol-Myers Squibb Company anticorpos para tigit
UA124143C2 (uk) 2015-05-20 2021-07-28 Янссен Байотек, Інк. Антитіла до cd38 для лікування амілоїдозу, викликаного відкладеннями легких ланцюгів імуноглобулінів, і інших cd38-позитивних злоякісних гематологічних новоутворень
TWI715587B (zh) 2015-05-28 2021-01-11 美商安可美德藥物股份有限公司 Ｔｉｇｉｔ結合劑和彼之用途
CR20180225A (es) 2015-09-25 2018-07-09 Genentech Inc Anticuerpo anti-tigit y métodos de uso
EP3548071A4 (en) 2016-11-30 2020-07-15 OncoMed Pharmaceuticals, Inc. METHOD FOR TREATING CANCER WITH TIGIT-BINDING ACTIVE SUBSTANCES
US11407830B2 (en) 2017-01-09 2022-08-09 Tesaro, Inc. Methods of treating cancer with anti-PD-1 antibodies
CN111050788A (zh) 2017-02-28 2020-04-21 西雅图基因公司 抗tigit抗体
CA3059468A1 (en) 2017-04-27 2018-11-01 Tesaro, Inc. Antibody agents directed against lymphocyte activation gene-3 (lag-3) and uses thereof
US11021537B2 (en) 2017-05-01 2021-06-01 Agenus Inc. Anti-TIGIT antibodies and methods of use thereof
JP7391027B2 (ja) 2018-02-26 2023-12-04 ジェネンテック， インコーポレイテッド 抗ｔｉｇｉｔ及び抗ｐｄ－ｌ１アンタゴニスト抗体による治療のための投薬
AU2019375409A1 (en) 2018-11-05 2021-05-27 Merck Sharp & Dohme Llc Dosing regimen of anti-TIGIT antibody for treatment of cancer

Also Published As

Publication number Publication date
CN102057272B (zh) 2015-02-18
KR101924831B1 (ko) 2018-12-05
WO2009126688A2 (en) 2009-10-15
IL272817A (en) 2020-04-30
JP6246158B2 (ja) 2017-12-13
IL228988A0 (en) 2013-12-31
US11390678B2 (en) 2022-07-19
US20230098521A1 (en) 2023-03-30
EP3208612B1 (en) 2019-09-18
KR101692080B1 (ko) 2017-01-02
ES2640533T3 (es) 2017-11-03
HUE036780T2 (hu) 2018-07-30
IL208285A0 (en) 2010-12-30
IL264498A (en) 2019-02-28
MX2010011088A (es) 2010-11-05
JP2020114211A (ja) 2020-07-30
SG10202112838YA (en) 2021-12-30
CA2719189A1 (en) 2009-10-15
DK2279412T3 (en) 2017-10-16
CN110082533A (zh) 2019-08-02
HK1211081A1 (en) 2016-05-13
KR20170004019A (ko) 2017-01-10
CN104655854A (zh) 2015-05-27
JP2021180663A (ja) 2021-11-25
EP2279412B1 (en) 2017-07-26
CN102057272A (zh) 2011-05-11
MX364200B (es) 2019-04-16
AU2009233708B2 (en) 2015-06-04
BRPI0906550A2 (pt) 2015-07-07
US20200317773A1 (en) 2020-10-08
EP3208612A1 (en) 2017-08-23
US20090258013A1 (en) 2009-10-15
KR20180049227A (ko) 2018-05-10
KR20180132156A (ko) 2018-12-11
ES2758126T3 (es) 2020-05-04
IL228988A (en) 2017-02-28
IL246293A0 (en) 2016-07-31
CA2905334A1 (en) 2009-10-15
AU2009233708A1 (en) 2009-10-15
IL264498B (en) 2020-07-30
JP2011523034A (ja) 2011-08-04
CN110082533B (zh) 2023-01-10
WO2009126688A3 (en) 2009-12-10
SI2279412T1 (sl) 2017-10-30
EP2279412A2 (en) 2011-02-02
JP2017215332A (ja) 2017-12-07
KR20100135892A (ko) 2010-12-27
CA3179151A1 (en) 2009-10-15
WO2009126688A8 (en) 2010-06-03
KR101855381B1 (ko) 2018-05-09
PL3208612T3 (pl) 2020-03-31
MX2018009945A (es) 2020-09-02
JP2019054793A (ja) 2019-04-11
US20170145093A1 (en) 2017-05-25
EP3605088A1 (en) 2020-02-05
JP2015178504A (ja) 2015-10-08
SG10201402815VA (en) 2014-09-26
IL246293B (en) 2019-02-28
JP5770624B2 (ja) 2015-08-26
BRPI0906550B1 (pt) 2021-11-30
JP2023055712A (ja) 2023-04-18
US9499596B2 (en) 2016-11-22
CA2719189C (en) 2020-08-04
BRPI0906550B8 (pt) 2022-01-11
US20130251720A1 (en) 2013-09-26

Similar Documents

Publication Publication Date Title
IL272817A (en) New preparations and methods for the treatment of vaccine-related diseases
EP2361089A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF ALTERED FUNCTION OF -SYNUCLEINE
EP2211881A4 (en) COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING DISEASES AFFECTING MAMMALS
HK1146894A1 (en) Compositions and methods for treating diseases of the nail
EP2125855A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER OR OTHER DISEASES
EP2432462A4 (en) OXYGEN PROCEDURE AND COMPOSITIONS FOR THE TREATMENT OF MAMMALIAN DISEASES
HK1159498A1 (en) Methods and compositions for the treatment of cancer
EP2331123A4 (en) COMPOSITIONS AND METHODS FOR TREATING HEPATITIS C
GB0718446D0 (en) Compositions and methods for the treatment of infection
EP2340027A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER
EP2515926A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF ANGIOGENESIS-RELATED OPHTHALMIC DISEASES
IL240560A0 (en) Preparations and methods for tumor diagnosis and treatment
EP2217238A4 (en) METHOD AND COMPOSITIONS FOR THE TREATMENT OF DISEASES RELATED TO PROTEINURIA
EP2271352A4 (en) COMPOSITIONS AND METHODS FOR TREATING NEOPLASTIC DISEASE
IL214349A0 (en) Compositions and methods for the treatment of cancer
EP2249789A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF XEROSOMY
EP2437738A4 (en) METHOD AND COMPOSITIONS FOR CANCER TREATMENT
EP2369936A4 (en) COMPOSITIONS AND METHODS OF TREATING AND PREVENTING FIBROTIC LENS DISEASES
EP2142566A4 (en) METHOD AND COMPOSITIONS FOR THE TREATMENT OF PROLIFERATIVE DISEASES
EP2285398A4 (en) METHOD AND COMPOSITIONS FOR TREATING ADIPOSITAS
EP2411031A4 (en) Methods and compositions for the treatment of cancer
EP2480099A4 (en) COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING METABOLIC DISEASES
PL2307380T3 (pl) Pochodne N’-nitroksyalkilonikotynamidu do leczenia chorób układu sercowo-naczyniowego
EP2467492A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF PROLIFERATIVE AND PATHOGENIC DISEASES
GB0808326D0 (en) Compositions and methods for the treatment of fybromyalgia